First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Codiak BioSciences, Inc.

    CDNA · 6 developments mapped · last assessed 2026-09-20

    Market Ontology has mapped 6 macro, policy, and market developments to Codiak BioSciences, Inc. since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for CDNA yet, so no modelled value is shown. The CDNA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run CDNA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for CDNA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Twist Bioscience partners with Eli Lilly on TuneLab AI discovery

      Increased competitive pressure in synthetic biology and antibody discovery services, potential for market share shifts.

      · Moves market share in synthetic biology tools, pricing power for services

    What changed, by assumption

    Market share in synthetic biology tools
    • 2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
    Market share in synthetic biology services
    • 2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platform
    Investor sentiment
    • 2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform
    Future partnership potential
    • 2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
    Market perception of biotech innovation
    • 2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactwatch1-3m0.20
    2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discoverywatch1-3m0.30
    2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discoverywatch1-3m0.20
    2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platformwatch1-3m0.30
    2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platformwatch3-12m0.30
    2026-09-19Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaborationwatch3-12m0.20